Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin by Church, F C et al.
THE JOURNAL OF BIOLOGICAL  CHEMISTRY 
0 1989 by The American Society for Biochemistry and Molecular Biology, Inc. 
Vol. 264, No. 6, Issue of February 25, pp. 3618-3623,1989 
Printed in U.S.A. 
Antithrombin Activity of Fucoidan 
(Received for publication, October 6, 1988) 
Frank C. Church$, James B. Meade, Rita E. Treanor,  and  Herbert C. Whinna 
From  the  Department of Pathology  and the  Center for Thrombosis  and  Hemostasis, the University of North Carolina 
School of Medicine,  Chapel  Hill,  North  Carolina 27599 
Fucoidan, poly(L-fucopyranose) linked  primarily 
a1 + 2  with  either  a C3- or a  C4-sulfate,  is an effective 
anticoagulant in vitro and in vivo (Springer, G .  F., 
Wurzel, H. A., McNeal, G .  M., Jr., Ansell, N. J., and 
Doughty, M. F. (1957) Proc. SOC. Exp. Biol. Med. 94, 
404-409). We have  determined  the  antithrombin  ef- 
fects of fucoidan on the glycosaminoglycan-binding 
plasma proteinase  inhibitors  antithrombin I11 and hep- 
arin cofactor 11. Fucoidan enhances the  heparin cofac- 
tor 11-thrombin reaction more than 3500-fold. The 
apparent second-order rate constant of thrombin  in- 
hibition by heparin cofactor I1 increases  from  4 % lo4 
(in  the absence of fucoidan) to 1.5 % los M” min” as 
the fucoidan concentration  increases from 0.1 to 10 pg/ 
ml and  then decreases as fucoidan is  increased above 
10 pg/ml. The fucoidan reaction  with  heparin cofactor 
11-thrombin is kinetically equivalent to a “template 
model.” Apparent  fucoidan-heparin cofactor I1 and  fu- 
coidan-thrombin dissociation constants are  370 and 1 
nM, respectively. The enhancement of thrombin  inhi- 
bition by fucoidan, like  heparin  and  dermatan  sulfate, 
is eliminated by selective chemical modification of ly- 
syl residues either of heparin cofactor I1 or of throm- 
bin. The  fucoidan-antithrombin I11 reactions  with 
thrombin and factor Xa are accelerated maximally 
285-  and 35-fold at fucoidan concentrations of 30 and 
500 pg/ml, respectively. Using human plasma and ”‘I- 
labeled thrombin in an ex vivo system, the heparin 
cofactor 11-thrombin  complex is formed preferentially 
over the antithrombin 111-thrombin complex in the 
presence of 10 pg/ml fucoidan. Our results indicate 
that heparin cofactor I1 is activated by fucoidan in 
vitro and  in  an ex vivo plasma system and suggest that 
the major antithrombin  activity of fucoidan in  vivo is 
mediated by heparin cofactor I1 and not  by antithrom- 
bin 111. 
Heparin is a glycosaminoglycan that has been widely used 
as a  therapeutic  anticoagulant (1). Interaction of heparin with 
the plasma proteinase inhibitor  antithrombin I11 is the pri- 
mary biochemical basis for the pharmacological effect. It is 
also thought that heparan sulfate proteoglycans on the surface 
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of endothelial cells serve as  the in vivo activator of antithrom- 
bin I11 (2). Antithrombin I11 inhibits all of the proteinases 
involved in the intrinsic coagulation pathway including fac- 
tors Xa, IXa, XIa, XIIa, kallikrein, and thrombin  (3).  Heparin 
cofactor I1 is another plasma protein that inhibits  thrombin 
but no other proteinases involved in intrinsic coagulation (4). 
Both  antithrombin I11 and heparin cofactor I1 inhibit  throm- 
bin by forming 1:l molar covalent complexes where throm- 
bin’s active site is blocked (3, 5, 6). I n  vitro, heparin greatly 
accelerates the rate of thrombin inhibition both by antithrom- 
bin I11 and by heparin cofactor I1  (6-8). Considerable evidence 
suggests that  the mechanism of action for the heparin-cata- 
lyzed thrombin inhibition by antithrombin  III/heparin cofac- 
tor I1 is through formation of a ternary complex between 
heparin, proteinase inhibitor,  and  proteinase (9-11). 
Unlike the antithrombin 111-thrombin reaction, the heparin 
cofactor 11-thrombin inhibition reaction is enhanced either 
by heparin or by dermatan sulfate (8, 12, 13). Structure- 
activity relationships of polyanion-heparin cofactor I1 inter- 
actions have shown that heparin cofactor I1 is activated by 
various glycosaminoglycans, polysaccharides, and carbox- 
ylate- and phosphate-containing polyanions (13). Thus, it 
appears that  the polyanion-binding region in heparin cofactor 
I1  is less discriminating than  the analogous heparin  (heparan 
sulfate)-binding region in  antithrombin 111. 
In 1957, Springer and associates (15) reported that fucoidan 
(a polymer of L-fucose linked primarily a1 + 2 with sulfates 
on the  three or four hydroxyls and with M ,  = 1 X lo6 (14)) 
from the brown marine alga Fucus uesiculosus, possesses 
anticoagulant activity in vitro and i n  vivo. Recently, Roberts 
et al. (16) have shown that fucoidan prevents sulfatide binding 
to  the adhesive proteins thrombospondin, laminin, and von 
Willebrand factor. Fucoidan also reverses bovine aortic endo- 
thelial cell spreading, and  it has specific effects on other cell- 
cell and cell-matrix adhesion reactions (17,18).  In the present 
paper, we have assessed the interaction of fucoidan with 
antithrombin I11 and heparin cofactor I1 as a contributing 
factor in the overall anticoagulant activity of this polysaccha- 
ride. We provide evidence that the antithrombin action of 
fucoidan (ex vivo in a plasma system) is mediated through 
heparin cofactor I1 and not through antithrombin 111, and 
this correlates well with the antithrombotic effect of fucoidan 
observed i n  vitro. 
EXPERIMENTAL PROCEDURES’ 
RESULTS AND DISCUSSION 
Effect of Fucoidan on Heparin Cofactor IZ- and  Antithrom- 
bin 111-Proteinase Inhibition Reactions-The antithrombin 
Portions of this paper (including “Experimental Procedures,” 
Figs.  1-7, and Table I) are presented in miniprint at  the end of this 
paper. Miniprint is easily read with the aid of a  standard magnifying 
glass. Full size photocopies are included in the microfilm edition of 
the Journal that is available from Waverly Press. 
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and  antifactor  Xa activities of heparin cofactor I1 and  anti- 
thrombin I11 were assessed by measuring the  rate of thrombin 
and factor Xa inhibition in the presence of fucoidan. Addition 
of fucoidan to heparin-cofactor II-thrombin at  pH 8.0 and 
25 "C enhanced the  rate of thrombin  inhibition. As shown in 
Fig. 1, the  rate of thrombin  inhibition by heparin cofactor 11 
either with fucoidan or with heparin (each at 100 ng/ml) 
resulted in an acceleration of 30- and 140-fold, respectively, 
over the heparin cofactor II-thrombin reaction determined in 
the absence of added polyanion. As found previously with 
heparin and  dermatan  sulfate (22), chymotrypsin inhibition 
by heparin cofactor I1 is not  enhanced by fucoidan (data  not 
shown). 
The relationship between the  rate of heparin cofactor II- 
thrombin inhibition and fucoidan concentration was deter- 
mined. The  rate  constant for thrombin  inhibition by heparin 
cofactor I1 increased in a polyanion-dependent manner from 
0.1 to 10 pg/ml, reached a maximum at 10 pg/ml, and  then 
decreased as fucoidan was increased above 10 pg/ml (Fig. 2). 
Under these reaction conditions, the rate  constant ( k ~ )  deter- 
mined for heparin cofactor II-thrombin at 10 pg/ml fucoidan 
was 1.5 X 10' M" min" and represents more than a 3500- 
fold increase over the inhibition rate in the absence of poly- 
anion (4 X IO4 M" min"). The shape of the curve suggests 
formation of a  ternary complex ("template model") with bind- 
ing of both  inhibitor  and  proteinase to fucoidan. This  template 
model has also been suggested for the inhibition of thrombin 
by heparin cofactor I1 in  the presence of heparin and  dermatan 
sulfate (9, 13). 
Addition of fucoidan (100 ng/ml) to antithrombin III- 
thrombin did not accelerate the  rate of thrombin  inhibition 
(using similar reaction conditions as in Fig. l), but heparin at 
the same concentration accelerated thrombin inhibition over 
90-fold (data not included). However, at higher concentra- 
tions of fucoidan, there was a measurable enhancement of the 
rate of thrombin  inhibition by antithrombin I11 that reached 
a maximum at about 30 pg/ml fucoidan (kz = 5.7 X lo7 M" 
min" compared to kz = 2 X 10' M" min" in the absence of 
polyanion; Fig. 2). The  rate of factor Xa  inhibition by anti- 
thrombin III-fucoidan as  a function of fucoidan concentration 
appeared to follow saturation kinetics, with a rapid rate 
increase between 1 and 100 pg/ml fucoidan and  a maximum 
(kz = 1 x lo7 M" min-l) as fucoidan approached 1 mg/ml 
(Fig. 3). An excess of fucoidan (100 pg/ml) decreased the  rate 
of factor Xa inhibition by antithrombin  III-heparin (1 pg/ml) 
(hobs (min") values are shown in parentheses):  antithrombin 
111 alone (0.31), heparin-antithrombin I11 (0.77), and  heparin- 
antithrombin I11 with fucoidan (0.36). The mechanisms for 
fucoidan acceleration of antithrombin  III-thrombin  and anti- 
thrombin  III-factor Xa inhibition appear to be similar to  that 
found for the heparin-catalyzed reactions (9-11). The results 
suggest that a  ternary complex is formed between fucoidan, 
antithrombin 111, and  thrombin. For factor Xa  and  antithrom- 
bin 111, the  data indicate an altered reactivity of either  pro- 
teinase  inhibitor  or  proteinase in the presence of fucoidan. 
Interaction of Fucoidan with Heparin Cofactor 11, Anti- 
thrombin III, and Thrombin-The interaction of fucoidan 
with these glycosaminoglycan-binding proteins was measured 
by chemical modification of lysyl residues, by altering buffer 
ionic strength  (with mono- and divalent ions), by monitoring 
changes in intrinsic  (antithrombin I11 and heparin cofactor 
11) and extrinsic (DEGR-thrombin)' fluorescence, and by 
* The abbreviations used are:  DEGR,  dansyl-Glu-Gly-Arg chloro- 
methylketone;  Tos-Gly-Pro-ArgNA, Nu-p-tosyl-Gly-Pro-Arg-p-ni- 
troanilide; aPTT, activated  partial  thromboplastin  time;  NaDodS04- 
PAGE,  sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 
evaluating the kinetic mechanism. 
The fucoidan-catalyzed heparin cofactor II-thrombin  inhi- 
bition reaction was studied by varying the heparin cofactor I1 
(Fig. 4A) and thrombin (Fig. 4 B )  concentration.  Saturation 
kinetics were observed with apparent dissociation constants 
for heparin cofactor II-fucoidan and thrombin-fucoidan of 
370 and 1 nM, respectively (Fig. 4). For comparison, apparent 
dissociation constants for antithrombin  III-heparin, heparin 
cofactor II-heparin,  and  thrombin-heparin  are 35,  230, and  7 
nM, respectively (9, 13). As shown for the proposed ternary 
complex model for the heparin-antithrombin III-thrombin 
reaction, the overall reaction velocity at optimum heparin 
concentration depends not only on the concentrations of 
antithrombin I11 and  thrombin but also on the tightness of 
inhibitor and proteinase binding to heparin (11, 28). The 
strength of the binding constants determined for heparin 
cofactor I1 and thrombin suggest that fucoidan interaction 
with both  inhibitor  and proteinase is important for the  cata- 
lytic effect. Furthermore, the dissociation constant for hepa- 
rin cofactor II-fucoidan is below the physiological heparin 
cofactor I1 concentration  and suggests a  potential use for this 
polysaccharide as an antithrombotic compound. 
Chemically modified proteins were used to  further probe 
the importance of fucoidan binding to  both heparin cofactor 
I1 and thrombin during the thrombin inhibition reaction. 
Modification of a limited number of lysyl residues either in 
heparin cofactor I1 or in thrombin resulted in essentially a 
complete loss (90 and >95% for heparin cofactor I1 and 
thrombin, respectively) of the fucoidan-catalyzed activity 
(Table I). Similar results were obtained when heparin or 
dermatan sulfate cofactor activity was measured with both 
modified proteins  (Table I).  The loss of polyanion cofactor 
activity following selective lysine modification suggests that 
these amino acid residues contribute to polyanion binding or 
that  their modification disables these binding sites.3 These 
results also demonstrate the importance of the binding of 
fucoidan (and heparin and  dermatan  sulfate)  to both heparin 
cofactor I1 and thrombin for enhancement of the rate of 
thrombin inhibition. 
The inhibition rate of heparin cofactor II-thrombin with 
fucoidan and heparin was determined as  a function of ionic 
strength. As shown in Fig.  5, there was a marked ionic strength 
dependence for thrombin inhibition with both the fucoidan 
and heparin. The loss of accelerated thrombin inhibition by 
heparin cofactor II-polyanions as  a function of ionic strength 
is likely  due to decreased binding of the polyanions to heparin 
cofactor I1 (heparin cofactor I1 and thrombin elute from 
immobilized heparin at 0.25 and 0.6 M NaC1, respectively). 
It has been shown previously that  the heparin-catalyzed 
antithrombin  III-thrombin inhibition rate is greatly decreased 
by calcium (29). The heparin (100 ng/ml)-catalyzed heparin 
cofactor II-thrombin reaction was inhibited more than 85%, 
with kz values of 1.3 x lo7 and 1.7 x IO6 M" min" in the 
absence and presence of calcium (10 mM), respectively. How- 
ever, the kz value for the fucoidan (100 ng/ml)-catalyzed 
heparin cofactor II-thrombin reaction was the same when 
Further  analysis of the  phosphopyridoxylation  reaction f heparin 
cofactor I1 in  the  absence  and presence of heparin  and fucoidan has 
been undertaken.  Both polysaccharides  reduce the  extent of protein 
lysine  modification by approximately 1 mol of reagent  incorporated 
per mol of heparin cofactor 11. High  performance liquid chromatog- 
raphy  peptide  maps  (tryptic  digests of reductively denatured  and S-  
carboxymethylated  protein) of phosphopyridoxylated  heparin cofac- 
tor 11, modified in  the  presence of heparin  or fucoidan, were identical 
and suggests that  these  sulfated polysaccharides protected  the  same 
lysyl residues (H. C. Whinna,  D. G. Klapper, M. R. Harris,  and F. C. 
Church (1988) J.  Cell. Biol. 107, 833a (Abstr.  4743)). 
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measured in the absence and presence of calcium (10 mM), 
3.4 X lo6 M" min". Calcium decreases the  apparent binding 
affinity of heparin for thrombin by binding to  the carboxyl 
groups of heparin (29). Absence of carboxyl groups in fucoidan 
would explain why calcium does not affect the fucoidan- 
catalyzed heparin cofactor 11-thrombin reaction. 
As found previously for heparin and dermatan sulfate, 
fucoidan did not induce a change in heparin cofactor I1 
intrinsic  protein fluorescence (data not included). And while 
the interaction between antithrombin I11 and heparin is read- 
ily detected by an intrinsic fluorescence increase, there was 
no change following the addition of fucoidan to  antithrombin 
I11 (Fig. 6A) .  However, fucoidan did eliminate the fluores- 
cence enhancement of the  antithrombin 111-heparin complex 
(Fig. 6B). The interaction of fucoidan with DEGR-thrombin 
resulted in  a %fold extrinsic fluorescence enhancement (data 
not shown). Nesheim et al. (11) showed a similar fluorescence 
change following the interaction of heparin with DEGR- 
thrombin. The signal change of DEGR-thrombin-heparin 
most likely represents an event subsequent to heparin-pro- 
teinase binding such as intermolecular thrombin  interactions 
(11). 
It has been shown recently that the "heparin-induced" 
conformation in  antithrombin I11 is not required to facilitate 
the inhibition of thrombin (28). Our results show that fucoi- 
dan is much less effective than heparin  during the  antithrom- 
bin 111-catalyzed thrombin and factor Xa inhibition reactions 
and that there is no detectable protein structural change 
following polysaccharide binding (determined by intrinsic 
fluorescence). Questions that arise are why does fucoidan 
accelerate the  antithrombin 111-catalyzed thrombin and factor 
Xa reactions and why does fucoidan eliminate the  antithrom- 
bin 111-heparin complex enhanced fluorescence signal? One 
possible explanation is that fucoidan binds to  (part of) the 
heparin binding site yet does not cause the same protein 
perturbation as does heparin. Another explanation is that 
steric hindrance follows fucoidan binding which either re- 
leases the heparin or modifies the heparin-antithrombin I11 
conformation (and quenches the enhanced protein fluores- 
cence). 
Heparin cofactor I1 and antithrombin I11 are very distinct 
thrombin  inhibitors  yet  they  share many structural  and func- 
tional properties. Perhaps  their most obvious similarity is the 
general effect of glycosaminoglycans during  thrombin  inhibi- 
tion (although heparin cofactor I1 reacts with a wider variety 
of polyanions). Much progress has been made on the location 
of the heparin binding site in antithrombin 111. The putative 
heparin binding site in antithrombin I11 consists of a region 
including Pro-41, Arg-47, Trp-49, and  the region surrounding 
lysyl residues 125, 133, and 136 (for review see Ref. 30). 
Computer-aided three-dimensional modeling studies of anti- 
thrombin I11 have revealed that these regions are adjacent to 
each other (31).4 Heparin cofactor I1 is similar to  antithrom- 
bin I11 both  in sequence (32) and in proposed three-dimen- 
sional structure (31)4 which may  allow identification of ho- 
mologous polyanion binding sites  in  heparin cofactor 11. As a 
further probe of possible similarities in  the heparin (polyan- 
ion) binding sites of heparin cofactor I1 and  antithrombin 111, 
we have diagrammed specific regions as Edmundson wheel 
plots (a-helical wheel projections assuming 3.6 amino acid 
residues/turn of the helix (33)): for antithrombin 111, this 
region was  Ala-124 to Val-141 and for heparin cofactor 11, the 
regions were Lys-173 to Leu-190 and Phe-183 to Arg-200. As 
shown in Fig.  7, the putative  heparin (polyanion) binding sites 
Church, F. C., Whinna,  H. C., Brown, R. L., Harris, M. R., and 
Pratt, C. W. (1989) J. Cell. Biochem. Suppl. 13A, abstract  in press. 
for both antithrombin I11 and heparin cofactor I1 yielded 
amphiphilic a-helices with positively charged and hydropho- 
bic amino acid residues located on opposite sides of the helix. 
Thus, a paradigm of  specific secondary structures (such as  an 
amphiphilic a-helix) and heparin-binding  domains might be 
established for these glycosaminoglycan-dependent protein- 
ase inhibitors. 
Fucoidan-catalyzed Thrombin Inhibition by Heparin Cofac- 
tor II in Plasma-The anticoagulant activity of fucoidan in 
plasma was examined using an activated partial thromboplas- 
tin time clotting assay. Clotting time was prolonged with 
increasing amounts of fucoidan (5-100 pg/ml; data  not in- 
cluded). Heparin (by weight) was about  12  times more potent 
as  an anticoagulant than fucoidan, essentially in agreement 
with the results of Springer  et al. (15). 
We next  determined  what  proteinase  inhibitor complexes 
were formed when thrombin was incubated with plasma in 
the presence of various amounts of fucoidan. Using this ex 
vivo system, '251-labeled thrombin was incubated either with 
plasma or with purified inhibitors and subsequently analyzed 
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
and autoradiography. Increasing amounts of fucoidan, to 10 
pglml, were correlated with preferential  incorporation of the 
radioactive thrombin into a covalent complex with heparin 
cofactor I1 (Fig. 8). The amount of radiolabeled thrombin 
incorporated into  an  antithrombin I11 complex did not in- 
crease in  the presence of fucoidan (Fig. 8). The physiological 
role of heparin cofactor I1 remains unclear although McGuire 
and Tollefsen (34) have recently suggested an  in vivo role for 
thrombin  inhibition by heparin cofactor I1 in the presence of 
extravascular components containing dermatan sulfate  pro- 
teoglycans. Our data also imply that  in vivo thrombin  inhibi- 
tion by heparin cofactor I1  may occur at  sites rich in  sulfate 
groups structurally  similar to fucoidan. 
Concluding Remark-Fucoidan, a sulfated polyfucopyra- 
nose, greatly accelerates the in vitro heparin cofactor II- 
thrombin  inhibition reaction. The heparin cofactor II-throm- 
bin complex is rapidly formed in the presence of 10 pg/ml 
fucoidan when '251-labeled thrombin is incubated with human 
plasma. These  results indicate that  the interaction of fucoidan 
with heparin cofactor 11, not  antithrombin 111, is important 
for the antithrombin activity of this polysaccharide. The 
FIG. 8. Activation of heparin cofactor I1 in human  plasma 
by fucoidan. Citrated-anticoagulated  plasma diluted 1:50 in   TNP 
buffer (50 mM triethanolamine acetate, 100 mM NaCl, and 0.1% 
polyethylene glycol, pH 8) or purified inhibitors  (diluted  to plasma 
concentration levels) were incubated with '251-labeled thrombin (5 
nM) for 10 min a t  25 "C with various amounts of fucoidan. The 
samples were then analyzed by sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis. An autoradiogram of the gel shows the 
positions of purified antithrombin 111-thrombin and  heparin cofactor 
11-thrombin  complexes in  the presence of 10 pg/ml  fucoidan (lanes 1 
and 2, respectively); the  plasma  system  with 0, 0.1, 1, and 10 pg/ml 
fucoidan (lanes 3-6, respectively); purified heparin cofactor I1 and 
antithrombin 111 mixed with  thrombin  and 10 pg/ml fucoidan (lane 
7); and purified antithrombin 111 and  heparin cofactor I1 with throm- 
bin  in  the absence of fucoidan (lanes 8 and 9, respectively). 
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characteristics of the fucoidan-catalyzed heparin cofactor II- 
thrombin reaction are  consistent with formation of a  ternary 
complex  which implies binding of both  proteinase  inhibitor 
and proteinase to fucoidan. Fucoidan and heparin binding 
sites in heparin cofactor I1 and thrombin are most likely 
localized to the same region in each protein. Finally, the 
results illustrate that  there  are  important functional/struc- 
tural differences and similarities between heparin cofactor I1 
and  antithrombin 111. 
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Heparin cofactor II actlvily was determlned by measuring the rate 
of thrombln  htbttton In the absence  and  Presence 01 Polyanlons 
essentially as descrlbed prevtously (19) Assays were started by addlng 
thrombin 15-10 nM) to a solut~on at 25OC and pH 8.0 containlng 50 mM 
lrlethanotamlne-acetate.  100 mM NaCl  and 0 1%  poly(ethyleneglyco1) 
(TNP  buffer).  heparln  cofactor 11 (25-100 nM) and the polyanlons  (at 
v a m u s  concentrations) At tlmed  Intervals.  portlons (0 1 mL) Were 
removed  and  added to a  substrate Solution (0 8 mL) Conlalnlng 0 3 mM 
TosGlyProArgNA m TNP buffer  and 0 1  mglmL  Polybrene  Substrate 
hydrolysis was terminated by addltlon of 0 1 mL 50% acetlc acld and the 
absorbance  was  measured at 404  nm.  Assays lor  the lnhlbmon 01 
thrombln  and factor Xa by antithrombin 1 1 1  were performed tn a similar 
manner  Chymotrypsln mhht ion  actlvlty of  hepar,"  cofactor I1 was 
determlned as detalled previously (22) Control  experlmenls Verlfled 
that fucoldan  dld not greatly aflect Substrate hydrolyses by the protein- 
ases  used In thls mvestigatlon Apparent pseudo f lrst Order (kobs)  and 
second order (k2) rate constants were calculated as descrlbed  (19). The 
antlcoagulant BctIvtIy of  tucoldan  was  measured  by  an  aPTT  clottlng 
assay [wtth varlous amounts of heparln (160 Uimg) from 0 to 1 UImL] 
tollowlng the procedure  provided by Pactl~c Hemostasis (23) 
The  present  lnvestlgatlon  assumes the lucoldan-catalyzed heparfn 
cofactor  Il-thrombln  reactton 1s analogous  to a blreaclant  enryme- 
catalyzed reactton that lollows a random order mechanism The klnetlc 
model and  assoc~at~on rate equations used were those for the  hepartn- 
Fucoidan 
Antithrombin  Action of Fucoidan 
accelerated  antithrombin 111 (and  heparm  cofactor  Il)-protelnase 
reactions  prevlousiy  described (9). Heparin  cofactor 11-thrombin 
concentratlon  sognificantiy  greater  than the lnotlal protelnase 
reactions were  performed In TNP buffer  wlth the  initlal  inhlbltor 
concentration Under these condltlons.  the  lucoidan-catalyzed  heparm 
cofactor  il-thrombln  reactmn  followed  apparent  pseudo-flrst  order 
klnetics  over the time  studled.  The  mitlal  reactlon veloctty (v , )  was 
caiculated  by  multlplymg  kobs by the lnlt!al thrombln concentratlon (9) 
Proteln concentrat~ons of heparin cofactor iI [M, I 65,600 (24)] and 
antithrombin  ill [M, = 56,600 (25)] were determined  at 280 nm wlth 
Speclflc absorptm  coefficlents of 0.593 and  0.624 mL mg- l  cm-1 ,  
respectlveiy (26). NaDodSOq-poiyacrylamIde gel electrophoresls  (PAGE) 
used  the  Laemmll  buffer  system  with 7 5% polyacrylamlde gels (27). 
Plasma  Incubation  with  radiolabeled-thrombin  and  autoradlography  were 
fluorescence  measurements were performed at 250C with TNP buffer  in 
performed  essentially  s  detailed  previously (8.23). lntrlnsic 
1.0-cm-pathlength  cuvettes  wlth  emtation at 280 nm and  emission 
scanned from 300 to 400 nm. BlndlnQ of heparln and fucoldan lo DEGR- 
dansyl  group  as  described (11). Spectrophotometric  and fluorometric 
thrombin  was monitored by  changes In extrinsic  fluorscence of the 
array  spectrophotometer  and  a Perkin  Elmer  LS-5  fluorometer, 
measurements  were  performed  ustng  aHewlett-Packard 845tA  dlode 
respectwely. 
CFUC010hNl Cpg/rnL) 
Flg. 3 Effect  of fuco ldan  concentrat ion    lac tor  Xa 
Inhibit ion  by  anti thrombin 111. Factor Xa (60 nM1 was  Incubated 
with antithrombin 111 (600 nM) in the  presence of varlous  concentrations 
of fucoidan in TNP butler Residual factor Xa  ctlvbty was measured as 
described  under 'Experimental Procedures"  The  rate  (k2)  of Factor Xa 
lnhibltlon  was  determlned  and  plotted as fold  activation  compared to the 
rate of lnhlbltbon (kp) In the absence of any added polyanion. 
[HEPARIN COFACTOR 111 CUM> tTWROMBINl <nM> 
R E A C T I O N  T I M E  C-od 
Flg. t E l lec t  of p o l y a n l o n s   o n   t h r o m b i n   i n h i b i t i o n   b y  
heparin  Cofactor 11. Thrombln  was  Incubated  wlth  epar,"  cofactor  Ii
(80-fold molar excess) at 25OC In TNP buffer in the absence of polyanlon 
(0 ) and  in the  presence of fucoldan (0 ) and  heparin ( A ) 
each  at 100 nglmL. Portlons were  withdrawn  at  intervals  and  assayed 
for  remalnlng  thrombin  activlty  as  described  under  'Experlmentai 
Procedures'. 
Cofactor 11-thrombin  reaction. The  mmal  rate ( Y , )  of thrombln 
Fig 4 K i n e t i c s  of the   luco idan-ca ta lyzed hepar in  
lnhiblllon by heparin  cofactor I1 (HC) ~n the  presence of 100  nglmL 
lucoldan was determined. ( A )  Initial  thrombfn  Concentrat~on was 5 nM 
(B) lnltlal HC concentration was 770 nM Data are  plotted as a Hanes- 
Woolfe  plot  according to the kmetlc model as  descrlbed  under  'Exper#- 
mental Procedures' 
<F"COIO*NI <"9,.L> 
Fig. 2 Effect  of luco idan  concentrat ion on th rombin  
inhibit ion  by  heparin  colactor I1 and  antithrombin 111. Thrombln  
antlthrombm 111 ( 5 0  nM) ( A ) IO  the presence 01 various concentrations 
( 5  nM) was mubated  wlth hepartn Cofactor I1 (75 nM) ( 0 ) and 
of fucoldan In TNP buffer.  Second order rate constant (kp) for thrornbm 
inhibttion  was  determlned  and the data  plotted  as  fold activation 
compared to the rate  of  lnhibltlon (kp) In the absence of any added 
polyamon 
Effect of Phonphopyridoxylation of Heparln  Cofactor II and 
TABLE I 
Thrombin  on  the  Polyanion-Catalyzed  Inhibit ion  Reactiona 
Protedn Polyanlon (0 1 pgImL) Loss of lnhlbltory Actlvlty 
................................................................ 
Hepar,"  Cofactor 1 1  Fucoidan 
Hepann 
Dermatan  Sulfate 
90 
7 a' 








aHeparln  cofactor iI  and thrombln  were  modlfled  wlth  pyrldoxal 
5'-phosphate as desertbed under 'Expermental Procedures'. Extent of 
mod,fcation was approxlmatsly 4 and 2 mol  reagent  mcorporated Per 
moi of  hepar,"  cofactor I1 and  thrombln, respectlvely 
bpercent  loss 01 mhibltory acttwty was  determloed  compared to 
Control p ro tem exposed only IO NaBH4 
Fucoidan 
Fucoidan Fucoida  
Fucoi an 
Fucoidan 
Antithrombin  Action of Fucoidan 3623 
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Fig. 5 Effect  of  i nic  strenoth  ont e  lucoidan-  and 
heparin-catalyzed  h parin  cotactor  II-lhrombin  reaction. 
Thrombm (5 "M) was Incubated wlth heparln cofactor I1 (75 nM) in the 
presence 01 10 pglmL lucoidan (.) or heparin (A) at PH 80 in 50 mM 
trlethanolamlne-acetate, 0.1%  poly(ethyleneglyc0l)  buffer at VarIOuS 
NaCi concentrations 
heparin-antithrombin 111 complex  intrinsic  fluorescence. 
Flg. 6 Effect  of  ucoidan  on  antithrombin 111 and 
(A)  
The change in mtrlnsc Iiuoresence 01 antithrombin i l l  (4  pM) in TNP 
bufter was measured In the absence of polyan~on (mlddle tracmg, so1,d 
Ihne) and in the presence of heparm (top tracmg, dotted Ihe) or fucoldan 
(bottom tracmg. dashed h e )  each at 250 WglmL (E) The change on 
IntrinSlC lluorescence of antithrombin Ill-hepar," complex ([anttthrom~ 
bln 1111 was 820 nM ana [hepar~n] was 125 pglmL) was measured m the 
absence (top traclng. dotted Ihne) and presence 01 fucoldan (680 VglmL) 
(mlddle tracmg, dashed h e )  lntrinslc  tlmrescence 01 antlthrombm Ill 
alone (mlddle traclng. solld Ihne) and fucoldan alone (bottom tracing, 
solid lhne) In TNP buffer 
in antithrombin 111 and heparin cofactor II. Sequences represent- 
Flg 7 Helical wheel plols of the heparin  binding  sites 
(ng putatlve  h patln  (polyanion)  bmdmg  sltes form amphlpathlc 
a-helices w l h  charged restdues and hydrophoblc resldues clustered on 
opposlte faces of the helw (for antithrambln 111. thts reglon was  Ala  124 
lo Val 141 and for heparm cofactor 1 1 .  the reglons were Lys 173 to Leu 
190 and Phe 183 to  Arg 200). These plots were prepared assuming 3 . 6  
amino acld residues per turn 01 the hellx ~n both protelns 
